Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Galderma Laboratories, L.P. v. Amneal Pharmaceuticals LLC, No. 19-1021 (Fed. Cir. Mar. 25, 2020)

Affirmed in Part
Infringement Doctrine of Equivalents Prosecution History Estoppel
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 19-1021
Decided
March 25, 2020
Judge
Moore, J.
Document
Nonprecedential Opinion
Length
15 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Appellees Galderma Laboratories, L.P., Nestle Skin Health S.A., and TCD Royalty Sub LLC (collectively, Gal- derma) sued Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals Co. (I) Pvt. Ltd. (n/k/a Amneal Pharma- ceuticals Pvt. Ltd.) (collectively, Amneal) for infringement of U.S. Patent Nos. 8,206,740, 8,394,405, and 8,470,364 (collectively, t he Chang Patents) and U.S. Patent Nos. 8,603,506 and 9,241,946 (collectively, the Ashley II Pa- tents).

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error